Analyst Calls XmAb819 Profile 'Unprecedented' as Shares Jump 20% to Near 52-Week High
XNCR has more than doubled off its 52-week low of $10.375 on elevated volume (4.8× avg).
Summary
William Blair's Matt Phipps called XmAb819's ccRCC profile 'unprecedented,' arguing the ESMO data represent a 'floor' for efficacy that can improve as CRS management gets better and the drug moves into less pretreated patients. The October follow-up adds color to the September cut: at the 400 mcg/kg dose, unconfirmed ORR hit 55% with 82% progression-free survival at six months, and median PFS has not yet been reached. Xencor has locked 400 mcg/kg as its proposed Phase 3 IV dose, with registration-enabling plans for late 2027 and FDA talks on accelerated approval for patients who have exhausted standard options. Shares rose 20.25% to $30.27, near the 52-week high of $30.61, following the 8-K filed this morning with the updated Phase 1 data. Watch for at least 20 evaluable patients at the 400 mcg/kg dose in early 2027, which management says will solidify the dose selection.
At the time of this announcement, XNCR was trading at $30.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $10.38 to $33.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.